Omnicell, Inc. (OMCL)

Market Cap	1.67B +23.1%
Revenue (ttm)	1.24B +5.6%
Net Income	44.67M +124.2%
EPS	0.96 +126.5%
Shares Out	45.61M
PE Ratio	38.04
Forward PE	18.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	785,476
Open	37.07
Previous Close	36.88
Day's Range	35.50 - 37.30
52-Week Range	30.69 - 55.00
Beta	0.99
Analysts	Strong Buy
Price Target	57.71 (+57.46%)
Earnings Date	Oct 29, 2026

About OMCL

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-hous...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Aug 7, 2001
• Employees: 3,485
• Stock Exchange: Nasdaq
• Ticker Symbol: OMCL
• Website: https://www.omnicell.com

Financial Performance

In 2025, Omnicell's revenue was $1.18 billion, an increase of 6.53% compared to the previous year's $1.11 billion. Earnings were $2.05 million, a decrease of -83.62%.

Analyst Summary

According to 7 analysts, the average rating for OMCL stock is "Strong Buy." The 12-month stock price target is $57.71, which is an increase of 57.46% from the latest price.

Price Target

$57.71

(57.46% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 31, 2026

Data Sources Report a data error